24/7 Market News Snapshot 20 October, 2025 – BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC)

October 20, 2025

DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (Nasdaq:BGLC) are discussed in this article.
BioNexus Gene Lab Corp (Nasdaq:BGLC) is experiencing a positive market trend, with its pre-market stock price rising to $5.259, which represents a 2.51% increase from the previous close of $5.130. This upward momentum is accompanied by a robust trading volume of 958.93K, indicating significant investor interest and favorable sentiment toward the stock. Technical indicators suggest the potential for continued growth, with established support levels near prior highs, although investors are advised to remain vigilant for any emerging resistance levels.

In conjunction with its promising market performance, BioNexus has announced a strategic partnership with BirchBioMed Inc., a biopharmaceutical company focused on regenerative therapies for conditions such as organ fibrosis and autoimmune diseases. The partnership, framed under a non-binding strategic term sheet, aims to accelerate the commercialization of Birch’s innovative FS2 topical platform in Southeast Asia.

As part of the collaboration, BGLC plans to spearhead Birch’s upcoming $10 million financing round, thereby enhancing growth initiatives through a strategic equity investment. This will involve BGLC issuing common shares representing 4.99 percent of its outstanding shares in exchange for 1.5 million common shares of Birch. The partnership seeks to synergize BGLC’s extensive market access and regulatory expertise with Birch’s advanced capabilities in dermal regeneration and fibrosis treatment.

Sam Tan, CEO of BioNexus, emphasized the significance of this collaboration, stating, “This strategic framework with BirchBioMed underscores our dedication to partnering with innovative biotech firms.” Mark S. Miller, CEO of BirchBioMed, expressed confidence in the partnership, highlighting it as a means to expedite the rollout of FS2 and enhance therapeutic innovations. As both companies progress toward a definitive agreement, their commitment to advancing biotechnology and improving global health outcomes remains a central focus.

Related news for (BGLC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.